🇺🇸 IMA901 in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dehydration — 2 reports (15.38%)
  2. Hyponatraemia — 2 reports (15.38%)
  3. Respiratory Failure — 2 reports (15.38%)
  4. Aortic Thrombosis — 1 report (7.69%)
  5. Disseminated Intravascular Coagulation — 1 report (7.69%)
  6. Extremity Necrosis — 1 report (7.69%)
  7. Hydrothorax — 1 report (7.69%)
  8. Hypocalcaemia — 1 report (7.69%)
  9. Hypomagnesaemia — 1 report (7.69%)
  10. Inappropriate Antidiuretic Hormone Secretion — 1 report (7.69%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is IMA901 approved in United States?

IMA901 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for IMA901 in United States?

Immatics Biotechnologies GmbH is the originator. The local marketing authorisation holder may differ — check the official source linked above.